These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21258877)

  • 21. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
    Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
    Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 23. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
    Jin J; Jiang DZ; Mai WY; Meng HT; Qian WB; Tong HY; Huang J; Mao LP; Tong Y; Wang L; Chen ZM; Xu WL
    Leukemia; 2006 Aug; 20(8):1361-7. PubMed ID: 16791270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
    Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
    Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
    Kantarjian HM; Keating MJ; Walters RS; Koller CA; McCredie KB; Freireich EJ
    Cancer; 1989 Mar; 63(5):813-7. PubMed ID: 2914287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
    Gu LF; Zhang WG; Wang FX; Cao XM; Chen YX; He AL; Liu J; Ma XR
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):997-1003. PubMed ID: 21152934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
    Bian SG; Hao YS; Wang ZC
    Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):22-5, 60. PubMed ID: 2401166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
    Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
    Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
    Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
    Chen C; Xu W; Yang J
    Leuk Lymphoma; 2015 Jan; 56(1):141-6. PubMed ID: 24724783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
    Ohtake S; Miyawaki S; Fujita H; Kiyoi H; Shinagawa K; Usui N; Okumura H; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
    Blood; 2011 Feb; 117(8):2358-65. PubMed ID: 20693429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
    J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study.
    Stewart JA; Cassileth PA; Bennett JM; O'Connell MJ
    Am J Clin Oncol; 1988 Dec; 11(6):627-9. PubMed ID: 3189228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
    Pluta A; Robak T; Wrzesien-Kus A; Katarzyna Budziszewska B; Sulek K; Wawrzyniak E; Czemerska M; Zwolinska M; Golos A; Holowiecka-Goral A; Kyrcz-Krzemien S; Piszcz J; Kloczko J; Mordak-Domagala M; Lange A; Razny M; Madry K; Wiktor-Jedrzejczak W; Grosicki S; Butrym A; Kuliczkowski K; Warzocha K; Holowiecki J; Giebel S; Szydlo R; Wierzbowska A
    Am J Hematol; 2017 Apr; 92(4):359-366. PubMed ID: 28103640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
    Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
    Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
    Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
    J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of 60 and 80 mg/m
    Vaezi M; Bahar B; Mousavi A; Yaghmai M; Kasaeian A; Souri M; Jahani M; Alimoghaddam K; Ghavamzadeh A
    Hematol Oncol; 2017 Mar; 35(1):101-105. PubMed ID: 26386260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.
    Fang B; Liu Y; Zhou J; Li Y; Song Y
    Am J Hematol; 2012 Jan; 87(1):126-7. PubMed ID: 22072502
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.